Ovarian cancer immunotherapy: non-standard solution — non-standard respons-Reference-Cited by-同舟云学术

Ovarian cancer immunotherapy: non-standard solution — non-standard respons

Published:2024-03-25 Issue:1 Volume:1 Page:49-55
ISSN:3034-1477
Container-title:Clinical Case in Oncology
language:
Short-container-title:jour

Author:

Gluzman M. I.¹^ORCID,Tyukavina N. V.²,Rudenko D. S.²,Orlova R. V.¹^ORCID

Affiliation:

1. St. Petersburg State University; City Clinical Oncology Dispensary

2. City Hospital No. 40

Abstract

Ovarian cancer is a serious problem in clinical oncology due to the frequent detection of the disease in late stages, as well as the extremely low effectiveness of treatment at the stage of development of resistance to platinum drugs. The use of immunotherapy in this setting is not a standard option, but several early phase trials of its potential effectiveness are described in the literature. This clinical case presents a successful experience with the use of immune checkpoint inhibitors in a pretreated patient with platinum-resistant metastatic ovarian cancer, which was accompanied by various immune-related adverse events.

Publisher

Association of Oncologist Real Clinical Practice OncoPractitioner

Reference26 articles.

1. Bowtell D.D., Böhm S., Ahmed A.A. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer // Nat. Rev. Cancer. 2015. Vol. 15. R. 668–679. doi: 10.1038/nrc4019.

2. Cannistra S.A. Cancer of the ovary // N. Engl. J. Med. 2004. Vol. 351. R. 2519–2529. doi: 10.1056/NEJMra041842.

3. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer. J. Clin. 2021. Vol. 71. R. 209–249. doi: 10.3322/caac.21660.

4. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial // Lancet Oncol. 2014. Vol. 15. R. 852–861. doi: 10.1016/S1470-2045(14)70228-1.

5. Ahmed A.A., Etemadmoghadam D., Temple J. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary // J. Pathol. 2010. Vol. 221. R. 49–56. doi: 10.1002/path.2696.